Plotting its first drug trial, Cambridge's Scholar Rock bags another $47M

The last we heard from Scholar Rock Inc., the Cambridge startup was unveiling plans in June to develop a drug for spinal muscular atrophy — the same rare infant disease for which Biogen scored a landmark FDA approval in December 2016. On Wednesday, the 45-employee company announced a significant new round of financing that its CEO described in no less ambitious terms: "The primary focus here is to build a blue-chip company," Nages h Mahanthappa said after closing the $47 million Series C financing. The…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news